G
Glaukos
Breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness
At a glance
- Founded
- 1998
- Headquarters
- Aliso Viejo, United States
- Listing
- IPO 2015
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Glaukos.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Versant Ventures- DVDeNovo Ventures
- BVBorealis Ventures
- DADomain Associates
- PMPrism Venture Management
- FPFrazier Healthcare Partners
Series B and later9 investors entered at this stage
Meritech Capital- UCUniversity of California
- IRIrvine
- FVFjord Ventures
InterWest Partners
OrbiMed- CACaltech
- CTCalifornia Institute of Technology
- MPMontreux Equity Partners
Source: Dealroom Talent Intelligence.
Alumni founders
Former Glaukos employees who went on to found companies, sorted by Dealroom signal score.
SMStylus MedicineEst. 2022
Joshua ResnickUnited States
Stig Visti AndersenDenmark
Alex GoraltchoukUnited States
Rahul ChaturvediUnited States
NMNalu MedicalEst. 2014
Mike PartschUnited StatesGlobal footprint
team presence
across markets
Patents
133 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Glaukos on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Glaukos on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.